I've written positively on Neurocrine Biosciences (NBIX)
twice already this year, and I finally took the plunge and bought it
for my own account. Although there's ample risk with this company's
clinical programs, the pipeline addresses some major unmet clinical
needs and could support a price target roughly double today's price.
Please click here for more:
Neurocrine Still Looks Significantly Underrated
No comments:
Post a Comment